Abstract: A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.

Abstract: A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.

Abstract: One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. For example, the treatment and/or prevention can be for laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.

Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.

Abstract: A SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, a SGLT2 inhibitor or a pharmaceutically acceptable form thereof is provided for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.

Abstract: The invention is directed to the use of a formulation comprising meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats. No negative effects on renal function occur following a treatment from 10 to 20 months or more.

Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.

Abstract: The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.

Abstract: The invention is directed to the use of a formulation comprising meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats. No negative effects on renal function occur following a treatment from 10 to 20 months or more.

Abstract: The invention is directed to a formulation containing NSAIDs or a pharmacologically acceptable salt thereof of and one or more vehicles for the treatment of kidney diseases in cats. Serum creatinine concentrations increase less over time following treatment with NSAID compared to untreated cats.

Abstract: The present invention generates a concise listing of low-priced travel products in an interactive itinerary format in response to a simplified user input that may include specification of a selected travel theme. The interactive itinerary generated by the invention may allow the user to revise the itinerary to add, remove, and/or amend details related to the various travel products listed therein such that the user may be made aware of the cost and/or scheduling effects of making a particular revision to the itinerary. The invention may also provide a concise display of supplemental information related to the selected theme and/or a selected destination for the itinerary such that the user may be better informed when making revisions to the interactive itinerary. For example, the invention may provide interactive maps, reviews, photos, and/or other supplemental information related to the selected theme and/or one or more of the listed travel products.

Abstract: The present invention generates a concise listing of low-priced travel products in an interactive itinerary format in response to a simplified user input that may include specification of a selected travel theme. The interactive itinerary generated by the invention may allow the user to revise the itinerary to add, remove, and/or amend details related to the various travel products listed therein such that the user may be made aware of the cost and/or scheduling effects of making a particular revision to the itinerary. The invention may also provide a concise display of supplemental information related to the selected theme and/or a selected destination for the itinerary such that the user may be better informed when making revisions to the interactive itinerary. For example, the invention may provide interactive maps, reviews, photos, and/or other supplemental information related to the selected theme and/or one or more of the listed travel products.